Camilla Jandus
Short bio
I am tenure-track Assistant Professor and Head of the “Targeting of cytokine secreting cell group (TCSL)” at the Department of Pathology and Immunology (PATIM) at the University of Geneva. I am also Adjunct scientist of the Lausann Branch of the Ludwig Institute for Cancer Resarch. I graduated in 2003 from the Faculty of Medicine at the University of Bern, Switzerland, after a training at the Memorial Sloan Kettering Cancer Center in New York, and the obtaining of my MD thesis from the Institute of Pathology in Bern. From 2004 to 2008 I performed my MD-PhD training at the Ludwig Institute for Cancer Research in Lausanne, in the group of Prof P. Romero. Then, I joined for a 2-year post-doctoral training the Pharmacology Institute in Bern. In 2012, I was appointed Associate Investigator at the Ludwig Center for Cancer Research at the University of Lausanne, where from 2015-2018 I was supported by an Ambizione Fellowship from the Swiss National Science Foundation (SNSF). In 2019 I have been appointed SNSF PRIMA Assistant Professor at the Department of Oncology, University of Lausanne and from January 2020 I have joined PATIM as tenure-track Assistant Professor.
Research
My main scientific interest is in the study of T cell- and Innate Lymphoid Cell (ILC)- mediated immune responses to human tumors. I have adopted and developed cutting-edge technologies for high-throughput analyses of T cells, at the single cell level, allowing to focus on the quantitative and qualitative evaluation of natural and therapy-induced tumor-specific CD4 T cell responses. I aim to identify the most potent T cells and best-of-class T cell receptors (TCRs), enabling their rapid and cost-effective isolation and validation in clinical trials. In parallel, I am investigating the role of Innate lymphoid cell (ILC) subsets, a recently described family of innate immune effector cells, in the context of anti-tumor immunity. I have been pioneering in reporting the pro-tumoral role of the ILC2 subset in human tumors and I am currently developing strategies to target these cells therapeutically in patients.
Selected publications
- Ercolano G., Gomez-Cadena A., Dumauthioz N., Vanoni G., Kreutzfeldt M., Wyss T., Michalik L., Loyon R., Ianaro A., Ho P-C., Borg C., Kopf M., Merkler D., Krebs P., Romero P., Trabanelli S. and Jandus C. PPAR drives IL-33 dependent ILC2 pro-tumoral functions. Nat Communications, 2021 May; 12(1):2538
- CachotA., BilousM., Liu Y-C., LiX., SaillardM., CenerentiM., RockingerGA., WyssT., GuillaumeP., SchmidtJ., GenoletR., ErcolanoG., ProttiMP., ReithW., IoannidouK., de LevalL., TrapaniJA., CoukosG., HarariA., SpeiserDE., MathisA., GfellerD., AltugH., RomeroP. and JandusC. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.Science Adv, 2021 Feb, 7(9):eabe3348
Salomé B., Gomez-Cadena A., Loyon R., Suffiotti M., Salvestrini V., Wyss T., Vanoni G., Ruan D.F., Rossi M., Tozzo A., Tentorio P., Bruni E., Riether C., Jacobsen E-V., Jandus P., Conrad C., Hoenig M., Schulz A., Michaud K., Della Porta M.G., Salvatore S., Ho P-C., Gfeller D., Ochsenbein A., Mavilio D., Curti A., Marcenaro E., Steinle A., Horowitz A., Romero P., Trabanelli S. and Jandus C. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Advances, 2019 Nov, 3(22):3674-3687 - Trabanelli S., Chevalier MF., Martinez-Usatorre A., Gomez-Cadena A., Salomé B.,Lecciso M., Salvestrini V., Verdeil G., Racle J., Papayannidis C., Morita H., Pizzitola I., Grandclément C., Bohner P., Bruni E., Girorta M., Pallavi R., Falvo P., Leibundgut EO., Baerlocher GM., Carlo-Stella C., Taurino D., Santoro A., Spinelli O., Rambaldi A., Giarin E., Basso G., Tresoldi C., Ciceri F., Gfeller D., Akdis CA., Mazzarella L., Minucci S., Pelicci PG., Marcenaro E., McKenzie ANJ., Vanhecke D., Coukos G., Mavilio D., Curti A., Derré L. and Jandus C. Tumor-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.Nat Commun, 2017Sep, 8(1):593
- Chevalier MF., Trabanelli S., Racle J., CessonV., Gharbi D., Bohner P., Domingos-PereiraS., Dartiguenave F., FritschiA-S., SpeiserDE., RentschCA., Gfeller D., JichlinskiP., Nardelli-HaefligerD., Jandus C.* and Derré L.*, ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. *: equal contribution. J Clin Invest, 2017 Aug, 127 (8):2916-2929